Project Grant R41HL182486
Award Date 9/15/25
Completion Date 2/28/26
Dollars Obligated $468K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, MA 02420, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $309,418 Project Grant to Oleolive, Inc. to develop an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The award, made on September 20, 2025, will support research to repurpose the FDA-approved drug pyrvinium as an inhalation treatment for IPF, a fatal lung disease affecting 40,000 U.S. patients annually. The project aims to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vast Therapeutics, Inc. a $2,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nitric oxide-releasing formulation (ALX1) for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients. The objective is to answer critical questions needed to initiate Phase II proof-of-concept clinical trials for this broad-spectrum antibacterial therapy,...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Vast Therapeutics, Inc. The grant, effective from September 11, 2025 to August 31, 2027, will support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for difficult non-tuberculous mycobacterial lung infections. The project aims to evaluate the pharmacokinetics and...
- This federal Project Grant award, valued at $155,227.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to generate proof-of-concept data on a novel strategy to treat Mycobacterium abscessus (MAB) chronic lung disease, which currently has no FDA-approved treatments. The strategy involves using a biofilm disruptor as an adjunct to antibiotics to more effectively...
- This Project Grant award of $800,679.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support the University of Virginia's research to interrogate the pathogenesis of chronic obstructive pulmonary disease (COPD) using metabolomics and genomics data. The objective is to expand the PredixCan method to incorporate metabolomics data, creating a new tool called MetaBoxCan, in order to extract more comprehensive mechanistic information from...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $284,699 to Aqualung Therapeutics, Corp, a biotechnology company, to optimize the dosage and evaluate the efficacy of their novel ALT-100 monoclonal antibody therapy in preclinical mouse models of lung fibrosis. The goal is to demonstrate the ability of ALT-100 to slow the progression of idiopathic pulmonary fibrosis (IPF), a severe and often...
- This $320,863 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a bifunctional IgE antagonist and dissociator (ANDI) to complement the existing monofunctional IgE inhibitor, Xolair, as a second-generation treatment for severe allergic asthma. The grant recipient, Aaiit LLC (doing business as Inflammation Immuno Therapy), will conduct research to investigate the...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a pharmaceutical research and development company based in Austin, Texas. The grant supports the development of an inhaled, fixed-dose combination powder product containing both azithromycin and amikacin for the treatment of non-tuberculous mycobacterial (NTM) infections. The goal is to improve...